VSPharmTech (VSPT), a clinical stage biotechnology company, has been dedicated to developing innovative therapeutics to achieve paradigm shift for cancer patients since its establishment in 2018. VSPT, whose leadership team is composed of experts with extensive experience in drug development and regulatory approval, has adopted a strategy of selecting high-potential drug candidates from leading research institutions in Korea and rapidly advancing them into clinical trials. The company has focused on optimizing the drug development process by leveraging technologies such as drug repurposing , Real World Evidence, Artificial Intelligence etc. As a result VSPT has secured 5 promising anticancer drug candidates, obtained 3 IND approvals from regulatory authorities in Korea and the U.S. Thanks to remarkable achievements in drug development, VSPT was designated an outstanding R&D SME company 2018-2023 in Korea and invited to JLABS, which is an incubation program by Johnson & Johnson.